

Supplementary Table S1. Detail of experimental vector preparations used for in vitro and in vivo experiments

Capsid	Promoter	Transgene	Titer	Experiment
AAV2	CBA	GFP	1.45×10^{13}	<i>In vitro</i> transduction study
TrpIYF	CBA	GFP	9.27×10^{12}	<i>In vitro</i> transduction study
TrpIYF + TV	CBA	GFP	8.90×10^{12}	<i>In vitro</i> transduction study
QuadYF	CBA	GFP	1.64×10^{13}	<i>In vitro</i> transduction study
QuadYF + TV	CBA	GFP	2.66×10^{13}	<i>In vitro</i> transduction study
AAV2	VECad	GFP	5.11×10^{13}	<i>In vivo</i> transduction study
QuadYF + TV	VECad	GFP	9.82×10^{12}	<i>In vivo</i> transduction study
	VECad	GFP	5.50×10^{13}	<i>In vivo</i> transduction study
	VECad	GFP	4.66×10^{13}	<i>In vivo</i> transduction study
AAV2	CMV-smVECad	Luc	1.52×10^{12}	<i>In vivo</i> bioluminescence study
QuadYF + TV	CMV-smVECad	Luc	4.44×10^{12}	<i>In vivo</i> bioluminescence study
AAV2	smCBA	mCherry	2.35×10^{12}	<i>In vitro</i> transduction study
QuadYF + TV	smCBA	mCherry	4.83×10^{12}	<i>In vitro</i> transduction study

AAV2, adeno-associated virus serotype 2; CBA, chicken β -actin; CMV, cytomegalovirus; CMV-smVECad, CMV enhanced small vascular endothelial cadherin; GFP, green fluorescent protein; Luc, firefly luciferase; mCherry, red fluorescent protein; QuadYF, QuadYF + TV, TrpIYF, TrpIYF + TV, AAV vectors incorporating up to five Y-F/T-V mutations (Y272F, Y444F, Y500F, Y730F, T491V); smCBA, small chicken β -actin; VECad, vascular endothelial cadherin.